AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03528252 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Written advice Triglycerides
Description: One A4 paper with written information on both sides
Study NCT01307605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide
Description: Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
Study NCT02297217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Taxol (paclitaxel)
Description: Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
Study NCT02297217 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation
Description: Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
Study NCT04174157 — intervention group
Intervention type: OTHER
Intervention: Prospective observational registry
Description: This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
Study NCT01029483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-carbohydrate ad libitum intervention
Description: Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
Study NCT01029483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate diet-energy matched intervention
Description: Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at \~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
Study NCT03437733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter
Study NCT01296113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~* Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~* Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total
Study NCT02344095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: weekly paclitaxel
Description: Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
Study NCT02344095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: weekly cisplatin
Description: Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
Study NCT02344095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oncothermia
Description: Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W.
Study NCT02058407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2793660 solution
Description: Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
Study NCT02058407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2793660 capsule
Description: Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
Study NCT02058407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: Matching placebo to GSK2793660 solution
Study NCT02058407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo to GSK2793660 capsule
Study NCT01631929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One bag
Description: Infusion of dextrose and electrolytes using one bag
Study NCT01631929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two bags
Description: Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
Study NCT02123511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine
Description: Oral rinse
Study NCT02123511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral rinse
Study NCT02123511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02123511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02123511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02123511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02105142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Group Visits
Description: Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
Study NCT02105142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Group Visits plus Online Discussion Portal
Description: Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
Study NCT02105142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Decision Support
Description: ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
Study NCT03426852 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00049309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Study NCT00049309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Study NCT00676637 — intervention group
Intervention type: DRUG
Intervention: Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)
Description: One drop in study eye(s) once daily in the evening for four months
Study NCT00676637 — intervention group
Intervention type: DEVICE
Intervention: Travalert Dosing Aid
Description: Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
Study NCT02143778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methacetin Breath Test
Description: 13C labelled methacetin solution for breath test monitoring
Study NCT04174157 — intervention group
Intervention type: DRUG
Intervention: Zolgensma
Description: Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
Study NCT00000249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% N2O
Description: 20% inhaled N2O
Study NCT00000249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% N2O
Description: 30% inhaled N2O
Study NCT01218256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise training
Description: aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
Study NCT03850431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Norms + Behavioral Instructions
Description: A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
Study NCT03850431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring + Consequences for Others + Behavioral Instructions
Description: A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
Study NCT03850431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring + Consequences for Self + Behavioral Instructions
Description: A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
Study NCT03850431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions
Description: A letter with all types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
Study NCT02718482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Docetaxel
Description: Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
Study NCT02718482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
Study NCT01034657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
Study NCT01034657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
Study NCT01797796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: 150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
Study NCT04508413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: KB295
Description: KB295 is a novel glycan
Study NCT01638299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypo-Hyper Minimizer (HHM) System
Description: Adjustment of Insulin dosing during meal time
Study NCT03863301 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided single dose preoperative PBI
Description: A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.
Study NCT02565186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: oral tablet
Study NCT03636269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 0.5 mcg/kg
Description: IV CR845 0.5 mcg/kg administered three times/week
Study NCT03636269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV placebo administered three times/week
Study NCT02091830 — intervention group
Intervention type: DRUG
Intervention: Paracetamol and nonsteroidal antiinflammatory drug (NSAID)
Study NCT02091830 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy
Study NCT02091830 — intervention group
Intervention type: DRUG
Intervention: Cortisone Injection
Study NCT02091830 — intervention group
Intervention type: OTHER
Intervention: Others
Study NCT00693732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram treatment
Description: On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
Study NCT00693732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Description: On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
Study NCT00693732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative sensory testing
Description: Rectal Distention Stimulation
Study NCT00693732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Description: Rectal Distention Stimulation
Study NCT02525432 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
Study NCT02525432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BMMNC Infusion
Description: In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
Study NCT01797796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin challenge
Description: 110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
Study NCT01797796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
Study NCT01797796 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin challenge
Description: 110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
Study NCT00816660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)
Description: Single dose, dose escalation, various cohorts
Study NCT00816660 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)
Description: Single dose, dose escalation, various cohorts
Study NCT00816660 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed plasma-derived VWF/FVIII concentrate
Description: Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
Study NCT02912429 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Patellofemoral Arthroplasty
Study NCT00415974 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physician Counseling
Description: Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
Study NCT00415974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Counseling
Description: Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
Study NCT00415974 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Educator
Description: Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
Study NCT00415974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Educator
Description: Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
Study NCT00415974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Counseling
Description: Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.